Legal analysis: for "due diligence" personnel, the cost of nucleic acid testing is borne by the medical insurance fund and the financial department, and individuals do not need to pay; For personnel other than "due diligence", they will be reimbursed according to the policies of employee medical insurance and resident medical insurance, and the part paid by individuals after medical insurance reimbursement will still be paid by individuals. However, the precautions for nucleic acid reimbursement must be clear, and it can only be reimbursed if it is tested in designated medical institutions, including my designated hospitals, designated Chinese medicine hospitals, designated specialized hospitals, and 19 designated class A medical institutions.

Legal basis: People's Republic of China (PRC) Law on the Prevention and Control of Infectious Diseases.

Twelfth all units and individuals in People's Republic of China (PRC) must accept the prevention and control measures such as investigation, inspection, sample collection and isolation treatment of infectious diseases by disease prevention and control institutions and medical institutions, and provide relevant information truthfully. Disease prevention and control institutions and medical institutions shall not disclose relevant information and materials involving personal privacy.

Where the administrative department of health and other relevant departments, disease prevention and control institutions and medical institutions illegally implement administrative management or prevention and control measures and infringe upon the legitimate rights and interests of units and individuals, the relevant units and individuals may apply for administrative reconsideration or bring a lawsuit according to law.

Article 17 The State shall establish a monitoring system for infectious diseases.

The health administrative department of the State Council formulated the national infectious disease monitoring plan and scheme. The health administrative departments of the people's governments of provinces, autonomous regions and municipalities directly under the Central Government shall, according to the national infectious disease monitoring plans and plans, formulate the infectious disease monitoring plans and work plans in their respective administrative regions.

Disease prevention and control institutions at all levels monitor the occurrence and prevalence of infectious diseases and the factors affecting their occurrence and prevalence; Monitor infectious diseases that have occurred abroad, not yet occurred in China or newly occurred in China.